Clinical trial

Comparison of Postoperative Recovery Quality Between Sevoflurane and Remimazolam for General Anesthesia for Transurethral Resection of Bladder Tumor

Name
QRST
Description
This study was designated to investigate the quality of recovery after transurethral bladder resection. Because, patients undergoing transurethral bladder resection are mostly old age, and because of catheter-related bladder discomfort are common after transurethral bladder resection, study on the quality of recovery after transurethral bladder resection seems to be meaningful. In general, sevoflurane is commonly used as an anesthetic agent for general anesthesia of transurethral bladder resection. The purpose of this study is to investigate whether remimazolam is not inferior to sevoflurnane in terms of quality of recovery after transurethral bladder resection.
Trial arms
Trial start
2022-12-02
Estimated PCD
2023-02-24
Trial end
2023-02-24
Status
Completed
Treatment
Sevoflurane
Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
Arms:
Sevoflurane
Remimazolam
Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
Arms:
Remimazolam
Size
36
Primary endpoint
Quality of recovery -15 score at postoperative day 1
postoperative day 1
Eligibility criteria
Inclusion Criteria: * adult patients aged from 19 years * Americaln Society of Anesthesiologist's class I, II, and III * scheduled to undergo elective transurethral bladder resection under general anesthesia Exclusion Criteria: * refuse to participate in the study * cannot read, or sign the consent form (e.g., iliterate, foreigner, eye disease) * history of allergy to benzodiazepines * decreased liver, kidney, or heart function * pregnant women or breastfeeding patients * history of drug or alcohol abuse * obesity (body mass index \> 30kg/m2)
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 36, 'type': 'ACTUAL'}}
Updated at
2023-03-09

1 organization

2 products

1 indication